Lax API testing lands Chinese CMO US FDA warning letter

By Flora Southey

- Last updated on GMT

(Image: Getty/triocean)
(Image: Getty/triocean)
The US FDA has sent a warning letter to Chinese contract manufacturing organisation Foshan Jinxiong Technology, which makes over-the-counter products for children.

The US Food and Drug Administration has placed Foshan Jinxiong Technology on Import Alert and issued a warning letter​ following an inspection at the contract manufacturing organisation’s (CMO’s) facility in Foshan City, Guangdong Province, in August last year.

According to the Agency, the firm – which makes over-the-counter (OTC) drug products for children – lacks adequate testing procedures for active pharmaceutical ingredients (APIs).

During the inspection, the FDA observed Foshan Jinxiong Technology had “released multiple lots of OTC drug product without data to support their conformance to specifications, including identity and strength.”

In addition, according to the FDA, the firm did not include a testing requirement to examine identity and strength of each lot prior to distribution: “You also did not provide active ingredient identity and strength test results of retain samples to support the quality of the drugs you have distributed to the US.”

Lax testing procedures for incoming ingredients was also flagged by the Agency: “Your firm failed to adequately test incoming components…for their identity. Instead, your firm relied on certificates of analysis (COA) from unqualified suppliers.”

The FDA ‘strongly recommends’ Foshan Jinxiong Technology employ a third-party consultant qualified to help address the current good manufacturing practice (cGMP) concerns.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more